The Epstein-Barr virus report covered all of the virus’s main characteristics, including its prevalence among humans, as the only carriers (Aliosis & Salvetti, 2022). Although the virus is transmitted through bodily fluids, it is common because it can lie dormant for many years (Patel et al., 2022). The virus, its antibodies, and the course of the disease are determined using a blood test (CDC, 2021). Treatment of the disease is minimal since antibiotics do not affect Epstein Barr, and the vaccine is not currently approved for use (Jacobs, 2018). However, this means that the virus remains permanently in the human body and leads to periodic exacerbations of the disease, during which the person is contagious (Jacobs, 2018). Therefore, studying the possible mechanisms of virus deactivation inside the carrier is essential. Scientists are studying new antiviral therapies and dendritic cell therapy as perspective approaches to curing EBV (Jacobs, 2018).
References
Aloisi, F., & Salvetti, M. (2022). Epstein-Barr virus and multiple sclerosis: Supporting causality. The Lancet Neurology, 21(4), 300-301. Web.
Centers for Disease Control and Prevention (CDC). About Epstein-Barr virus (EBV). (2021). Web.
Jacobs, E. (2018). Etiology of Chronic Disease: A Discussion on Ep-stein-Barr Virus. J Cancer Biol Treat, 5, 014.
Patel, P. D., Rahmah, A., Afshan, H., Maheshwari, M. V., & Nabeeha, K. (2022). The Association of Epstein-Barr Virus with Cancer. Cureus, 14(6). Web.